Vijaya Diagnostic Centre Ltd (VIJAYA) Q2FY26 Concall Summary - Sep-2025 Qtr
Performance Overview
- Vijaya Diagnostic Centre Ltd reported a consolidated revenue of Rs.202 crores for the Sep-2025 quarter, marking a 10.2% year-on-year and 7.2% quarter-on-quarter growth, primarily driven by an 8.3% year-on-year increase in test volume.
- The company maintained a strong EBITDA margin of 40.6% and a healthy PAT margin of 21.5%, reflecting the resilience of its business model and encouraging performance from newly launched hub centres.
- The Yelahanka Hub Centre in Bengaluru achieved break-even within just two quarters, significantly ahead of the projected one-year timeline, underscoring strong demand for integrated diagnostics.
- The merger of Medinova Diagnostic Services Limited with the company received NCLT approval in October, effective April 1, 2024.
- The company commenced Q3 FY26 on a positive note, observing a notable increase in footfalls and revenue across its network.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.